pHLIP, Inc is a clinical-stage biopharmaceutical company dedicated to improving patient health by using our peptide-based targeted delivery platform to treat acidic tissue diseases. pHLIP, Inc. was founded to bring its proprietary pHLIP® (pH-Low Insertion Peptide) Platform Technology to the clinic, improving the treatment of diseases where visualization and/or targeted therapy would be highly advantageous. pHLIP® peptides target metabolically active (glycolytic and acidic) cells in diseased tissues, where they insert directionally across the cell membrane. Therapeutic or imaging molecules can be anchored to the surfaces of acidic diseased cells or translocated and released directly into acidic diseased cells by pHLIP® peptides. The technology has been licensed from Yale, the University of Rhode Island, and the Memorial Sloan Kettering Cancer Center, and the licenses include exclusive Worldwide commercial rights to the extensive pH peptide patent families and pHLIP® trademark. For more information, visit www.philipinc.com

 

 

Learn How URI Ventures Can Help You

Request a meeting to discuss your specific needs.